

## HERAMED LIMITED COMPLETES FURTHER \$1 MILLION INSTITUTIONAL PLACEMENT

- HeraMED received and accepted a further \$1.02 million (before costs) investment proposal from 3 institutional investors. This placement will be subject to shareholder approval.
- \$1.02 million Placement at 1.7 cents per share, a ~19% discount to the 15-day VWAP of 2.1 cents (the same terms as the recently completed capital raising).
- The proceeds of the Placement will further strengthen the Company's financial position. Additionally, the funds will allow HeraMED to accelerate and expand the Company's four-point plan, in particular, the grant and non-dilutive strategy with dedicated resources.

**HeraMED Limited (ASX: HMD)** ('HeraMED' or the 'Company'), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce it received and has accepted a further investment offer via a private Placement (the "**Placement**") of \$1.02 million (before costs) from 3 leading institutional investors including HeraMED's first investment from a leading impact fund.

**HeraMED Managing Director and CEO, Anoushka Gungadin, commented,** "This strategic investment marks a transformative moment in our journey. This investment provides us with additional capital to drive our growth but also validates our commitment to delivering positive social impact in the healthcare sector. The global healthcare landscape faces mounting challenges in care accessibility, workforce shortages, and escalating costs. HeraCARE continues to demonstrate its potential as a comprehensive solution to these pressing issues, with an expanding body of evidence supporting its efficacy.

These Placement funds strengthen the Company's financial position and provide an ability to drive both the HeraCARE commercialisation strategy, while building a sustainable pipeline of non-dilutive funding through grants and research partnerships. HeraMED will continue to expand its research collaborations and developing new evidence-based care models that can make a real difference in pregnancy outcomes across diverse communities.

In 2024 the number and value of grants connected to remote maternity care significantly increased in Australia, the US and Europe. To ensure HeraMED is successfully applying and winning these grants it needs to invest in dedicated resources. Additional investment in our grant and non-dilution strategy will increase the probability of successfully obtaining grants.

The maternal health sector is at a critical juncture where technology can play a pivotal role in improving access and outcomes. This investment will help us scale our solutions and create meaningful impact in communities where it's needed most."

### About the Placement

HeraMED has received firm commitments to raise a further \$1.02 million (before costs) via the issue of 60,000,000 new ordinary shares, at 1.7 cents per share in a private Placement on the same terms as the recently completed capital raise announced on 23 October 2024, subject to shareholder approval at its upcoming Extraordinary General Meeting 'EGM'. The issue price is a 19% discount to the 15-day VWAP of 2.1 cents from the last closing price on Friday, 8<sup>th</sup> November 2024.

Westar Capital Limited managed the Placement and will receive a 6% capital raising fee on completion.

The indicative timetable for the Placement is as follows:

Summary of key dates	Date/Time
ASX Announcement of Offer	11 November 2024
EGM - to approve the issue of Placement Shares	12 December 2024
Settlement of Placement Shares	16 December 2024
Allotment and trading of Placement Shares	17 December 2024

The above timetable is indicative only and may change without notice.

ENDS

This announcement has been authorised by the Board of HeraMED Limited.

**HeraMED Limited**  
**Managing Director & CEO**  
Anoushka Gungadin  
M: +61 431 131 649  
E: [anoushka@hera-med.com](mailto:anoushka@hera-med.com)

**CFO & Company Secretary**  
Cameron Jones  
T: +61 400 086 399  
E: [cameron.jones@bio101.com](mailto:cameron.jones@bio101.com)

**Chairman**  
Tim Chapman  
T: +61 419 897 062  
E: [tchapman@claritycap.com.au](mailto:tchapman@claritycap.com.au)

## About HeraMED Limited (ASX: HMD)

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.